Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$47.19 USD

47.19
438,056

-1.25 (-2.58%)

Updated Jun 13, 2024 10:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 249)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Intercept (ICPT) Releases Data from Phase II Flint Trial

Intercept Pharmaceuticals, Inc. (ICPT) announced a retrospective analysis of the phase II trial, FLINT, in patients who were diagnosed with nonalcoholic steatohepatitis (NASH) and type II diabetes.

    Valeant Inks Deal to Divest iNova Pharmaceuticals for $930M

    Valeant Pharmaceuticals International, Inc. (VRX) announced that it has signed a deal to sell iNova Pharmaceuticals for $930 million in cash to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group.

      Ryan McQueeney headshot

      3 Large Cap Pharma Stocks to Buy Now

      Despite the uncertainty looming over the healthcare business, drug stocks have been doing well so far this year. Check out these three large cap pharma stocks to buy now!

        Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies

        Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that their PCSK9 inhibitor, Praluent significantly reduced bad cholesterol in two late-stage studies.

          Is the Options Market Predicting a Spike in Sanofi (SNY) Stock?

          Investors in Sanofi (SNY) need to pay close attention to the stock based on moves in the options market lately.

            Amgen Files for Repatha in the U.S., EU for Expanded Use

            Biotech major, Amgen, Inc. (AMGN) announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU.

              Sanofi (SNY): Strong Industry, Solid Earnings Estimate Revisions

              One stock that might be an intriguing choice for investors right now is Sanofi (SNY).

                Regeneron Announces Positive Data on Carcinoma Candidate

                Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).

                  Big Pharma Diabetes Drugs Not So Sweet. What's in Store?

                  Aales of diabetes drugs from most large pharma companies slipped in the first quarter.

                    Arpita Dutt headshot

                    5 Drug Stocks in Focus on World MS Day

                    Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.

                      Will Regeneron's (REGN) Newly Approved Drugs Drive Growth?

                      We believe approval of new drugs at Regeneron will lessen the company's dependence on Eylea.

                        Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

                        After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

                          Arpita Dutt headshot

                          Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

                          Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.

                            Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline

                            We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.

                              Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

                              Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.

                                Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog

                                Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).

                                  Arpita Dutt headshot

                                  Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings?

                                  Merck (MRK) and Sanofi (SNY) are both Zacks Rank #2 (Buy) stocks. Which company looks better-positioned for the remainder of the year?

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

                                    This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.

                                      Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1

                                      Immune Design Corp. (IMDZ) reported first-quarter 2017 loss of 50 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a year-ago loss of 61 cents.

                                        Kevin Cook headshot

                                        Bull of the Day: Regeneron (REGN)

                                        Shares launched 25% recently as Kevzara and the launch of Dupixent are expected to reignite sales growth

                                          AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher

                                          AstraZeneca PLC (AZN) shares rose above 9% in the last trading session.

                                            Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan

                                            Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period

                                              Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y

                                              Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.

                                                Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat

                                                Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents

                                                  BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up

                                                  BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.